Tesamorlin

Plasma Concentration Studies

Tesamorlin

EGRIFTA

TH9507

A 44-amino acid GHRH analog that stimulates pituitary gh secretion, studied for visceral adipose tissue reduction in clinical research. Premium Research Peptide.

Certificate of Analysis

Third Party Tested by Freedom Diagnostics

Coming soon!

Sources & References

Peer-reviewed research

Journal of Clinical Endocrinology & Metabolism

Effects of tesamorlin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fa...

2010

PMID: 20554713

Falutz J, et al.

  • View Source

Lancet HIV

Effects of tesamorlin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind,...

2019

PMID: 31611038

Stanley TL, et al.

  • View Source

Archives of Neurology

Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive...

2012

PMID: 22869065

Baker LD, et al.

  • View Source

Journal of Clinical Endocrinology & Metabolism

The Growth Hormone Releasing Hormone Analogue, Tesamorlin, Decreases Muscle Fat and Increases...

2019

PMID: 31050749

Adrian S, et al.

  • View Source

JCI Insight

Effects of tesamorlin on hepatic transcriptomic signatures in HIV-associated NAFLD

2020

PMID: 32780726

Fourman LT, et al.

  • View Source

FDA

EGRIFTA (tesamorlin) Prescribing Information

2025

Theratechnologies Inc.

  • View Source
All the research peptides you need, with the peace of mind and research community at your fingertips.
Discover More

Research Verification

Pèptido Labs sells research peptides exclusively to qualified researchers and laboratories for in vitro and laboratory use. Please confirm before continuing.

By proceeding you affirm the statements above are true. Products are not for human or veterinary use, not for use in diagnostic procedures, and have not been evaluated by the U.S. Food and Drug Administration.